Crinetics Pharmaceuticals, Inc. — Director's Dealing 2020

Apr 29, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Crinetics Pharmaceuticals, Inc. (CRNX)
CIK: 0001658247
Period of Report: 2020-04-28

Reporting Person: WIERENGA WENDALL (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-04-28	Common Stock	M	25329	$0.73	Acquired	99846	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-04-28	Stock Option (right to but)	$0.73	M	25329	Disposed	2025-12-10	Common Stock (25329)	Direct

Footnotes

F1: 25% of the shares subject to the option vested on October 30, 2016, and 1/48th of the shares subject to the option vested monthly thereafter such that all of the shares subject to the option were fully vested as of October 30, 2019.